2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

曲妥珠单抗 医学 内科学 危险系数 乳腺癌 临床终点 肿瘤科 不利影响 临床试验 外科 佐剂 癌症 置信区间
作者
Aron Goldhirsch,Richard D. Gelber,Martine J Piccart,Evandro de Azambuja,Marion Jennifer Procter,Thomas M. Suter,Christian Jackisch,David Cameron,Harald Weber,Dominik Heinzmann,Lissandra Dal Lago,Eleanor T. Mcfadden,Mitch Dowsett,Michael Untch,Luca Gianni,Richard H. Bell,C.-H. Köhne,Anita Vindevoghel,Michael Andersson,Adrian Murray Brunt
出处
期刊:The Lancet [Elsevier BV]
卷期号:382 (9897): 1021-1028 被引量:498
标识
DOI:10.1016/s0140-6736(13)61094-6
摘要

Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were disease-free 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of 1 year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.gov, number NCT00045032.We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0·99, 95% CI 0·85-1·14, p=0·86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group (342 [20·4%] vs 275 [16·3%] grade 3-4 adverse events, and 120 [7·2%] vs 69 [4·1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0·76 (95% CI 0·67-0·86, p<0·0001) for disease-free survival and 0·76 (0·65-0·88, p=0·0005) for overall survival, despite crossover of 884 (52%) patients from the observation group to trastuzumab therapy.2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer. 1 year of treatment provides a significant disease-free and overall survival benefit compared with observation and remains the standard of care.F Hoffmann-La Roche (Roche).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様的应助被NAN采纳,获得10
刚刚
刚刚
1秒前
忧郁的莫茗完成签到,获得积分10
2秒前
小橘完成签到,获得积分10
4秒前
李爱国的应助被科研不是科幻采纳,获得10
4秒前
4秒前
5秒前
enkidu发布了新的文献求助10
5秒前
也未可知完成签到 ,获得积分0
5秒前
5秒前
丹丹完成签到 ,获得积分10
5秒前
yian007发布了新的文献求助10
6秒前
香辣牛排发布了新的文献求助10
6秒前
6秒前
孔之如冬完成签到 ,获得积分10
6秒前
6秒前
7秒前
chan完成签到,获得积分10
7秒前
秋风的应助被郦稀采纳,获得10
7秒前
杨青黄发布了新的文献求助10
8秒前
9秒前
mhx1234567890完成签到,获得积分20
9秒前
cjr发布了新的文献求助10
9秒前
xiejie发布了新的文献求助10
9秒前
科烟生完成签到,获得积分10
9秒前
10秒前
所所的应助被果粒橙采纳,获得10
10秒前
10秒前
huang完成签到,获得积分10
11秒前
小羊发布了新的文献求助10
12秒前
Gilhog完成签到,获得积分10
12秒前
小蘑菇的应助被PhDL1采纳,获得10
12秒前
光亮绮山完成签到,获得积分10
12秒前
Nothing完成签到,获得积分10
13秒前
14秒前
14秒前
14秒前
14秒前
3475发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593